AI in pharma and life sciences is an easy “sell,” yet delivering real value remains a formidable challenge. Progress is most often hampered by closed data, weak data sharing, and inflated expectations. In this interview with Marcin Wawryszczuk (PhD, MBA) — Head of AI at Andersen and an AI researcher — we discuss how data platforms are becoming the bottleneck, whether it is possible to distinguish a viable project from a mere demo, and why, in production, resilience to drift and explainability of results outweigh impressive metrics.
The FDA, through its Center for Biologics Evaluation and Research (CBER), has informed manufacturers of several widely used influenza vaccines that safety information must be updated after post-marketing surveillance data revealed a small but statistically significant increase in the risk of febrile seizures in young children shortly after vaccination.
Personalized medicine is becoming the infrastructural element of healthcare. We discuss how AI acceleration, falling DNA sequencing costs, and government funding are driving this massive industry change.
As the year draws to a close, major analytics firms traditionally share their view on where the medtech industry is heading and what to expect in the near future. We have gone through these reports and distilled the essentials: from the explosive growth of AI in medical devices and the portable tech market to regional regulatory specifics and shifting investment priorities. This article brings together the key figures, insights, and directions that will shape medtech over the coming years.